Compare Immunovant Inc. Common Stock (IMVT) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Invesco Ltd. — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Invesco Ltd. trades at $30.09 (market cap $13.28B). The key difference: Invesco Ltd. is far larger — about 2.1× Immunovant Inc. Common Stock's market cap, and Invesco Ltd. pays a 2.86% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Invesco Ltd. for 77 Days on average.
| IMVT | IVZ | |
|---|---|---|
Market Cap | $6.25B | $13.28B |
Volume | 1,755,411 | 3,698,033 |
Sector | Health | Financials |
52-Week High | $44.96 | $33.31 |
52-Week Low | $17.03 | $22.44 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $5.35B | $23.45B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Invesco (IVZ) trades at $30.50, showing modest daily gains of 0.39%. The stock presents mixed signals with bearish technical indicators but positive analyst sentiment featuring 12 buy ratings and a $33.71 consensus target. Recent financials show revenue growth to $6.38B in 2025, though net income remains negative at -$281.70M. The company maintains strong operating cash flow of $1.53B and recently announced a $0.22 dividend for H2-2026.
Investment outlook balances analyst optimism against fundamental challenges. The 8.8% upside to consensus target suggests potential, but negative profitability metrics and bearish technicals warrant caution. Key catalysts include Q3 2026 earnings release on October 27 and continued AUM growth momentum, while risks center on margin pressure and market volatility affecting asset management revenues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
